People with early breast cancer usually get treatment after surgery, even if the surgery was successful. This is called adjuvant treatment.
After early breast cancer surgery, PERJETA is approved in combination with Herceptin® (trastuzumab) and chemotherapy for people with HER2+ early breast cancer that has a high likelihood of coming back.
Adjuvant treatment is given with curative intent to kill any cancer cells left behind after surgery, with the goal of keeping you cancer-free for as long as possible.
Keep in mind that even if you get adjuvant treatment, the cancer may still return. In addition, some people may experience serious or common side effects while receiving adjuvant treatment.
You may be eligible to receive PERJETA + Herceptin-based treatment after surgery if you have HER2+ early breast cancer and:
If you and your doctor decide that PERJETA + Herceptin-based treatment after surgery is right for you, your treatment plan might look like this:
Starting PERJETA + Herceptin-based therapy after surgery
*Unless side effects become too difficult to manage, or the cancer comes back sooner.
You should receive a total of 1 year (up to 18 cycles) of treatment with PERJETA and Herceptin. This includes any PERJETA and Herceptin you may have been given before surgery. Your treatment may be stopped sooner if your side effects become too difficult to manage or if the cancer comes back.
You will also be given chemotherapy; the dosing schedule and number of cycles will depend on which type of chemotherapy you receive. Your doctor will decide what chemotherapy regimen is right for you. Although a complete course of PERJETA + Herceptin-based therapy is a full year, chemotherapy is typically stopped sooner.
Cycle: A course of treatment that is repeated on a regular schedule with periods of rest in between. For example, PERJETA + Herceptin is given once every 3 weeks. That is one cycle.
Use the information below to see how many PERJETA + Herceptin cycles you have remaining.
*Unless side effects become too difficult to manage, or the cancer comes back sooner.
This information is for reference purposes only. Please consult with your healthcare team regarding your full course of treatment. Your doctor may discontinue your treatment if side effects become too difficult to manage or if your cancer comes back.
What are the possible side effects of PERJETA? PERJETA may cause serious side effects, including:
Who should not take PERJETA?
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.
What are the other possible side effects of PERJETA? Serious side effects of PERJETA may also include:
Possible serious and sometimes fatal side effects of PERJETA include infusion-related reactions and severe allergic reactions (hypersensitivity reactions/anaphylaxis).
See additional Important Safety Information below.
PERJETA + Herceptin-based therapy after surgery has been shown to lower the risk of the cancer coming back in certain people who have HER2+ early breast cancer.
Discover another treatment — an injection that's given in minutes.
See how PERJETA + Herceptin-based therapy is given and what you may expect during your infusion.
Discover information and resources to help you have an informative conversation with your doctor.
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and chemotherapy for use after surgery (adjuvant treatment) in adults with HER2-positive early breast cancer that has a high likelihood of coming back.
Perjeta is given through an IV infusion in a healthcare setting. The initial dose is 840 mg infused over 60 minutes, followed every three weeks by a dose of 420 mg infused over 30-60 minutes.
Serious side effects of Perjeta include heart problems, death of an unborn baby, and birth defects. Perjeta should not be used in patients who are allergic to Perjeta or to any of the ingredients in Perjeta. Other possible serious and sometimes fatal side effects include infusion-related reactions and severe allergic reactions. The most common side effects of Perjeta when given with trastuzumab and chemotherapy after surgery for early breast cancer include diarrhea, nausea, hair loss, fatigue, damage to the nerves, and vomiting.
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and chemotherapy for:
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with trastuzumab and docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received prior anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PERJETA may cause serious side effects, including:
PERJETA can cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure)
Receiving PERJETA during pregnancy can cause the death of an unborn baby and birth defects
PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA.
Serious side effects of PERJETA may also include:
The most common side effects of PERJETA when given with trastuzumab and chemotherapy prior to surgery for early breast cancer include:
The most common side effects of PERJETA when given with trastuzumab and chemotherapy after surgery for early breast cancer include:
The most common side effects of PERJETA when given with trastuzumab and docetaxel for metastatic breast cancer include:
Side effects may vary based on chemotherapy regimen. These are not all the possible side effects of PERJETA. Call your healthcare provider for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-877-436-3683.
Before you take PERJETA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Please see the full Prescribing Information for additional Important Safety Information, including most serious side effects.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.